BPC-157 / TB-500 Blend Research Guide: Synergistic Tissue Repair

The BPC-157 / TB-500 Blend is a combined lyophilised research preparation containing equal proportions of BPC-157 (Body Protection Compound-157) and TB-500 (Thymosin Beta-4 synthetic analogue). The two peptides are among the most extensively investigated compounds in preclinical tissue repair research, and their mechanistic profiles are complementary rather than redundant — making the combination a logical choice for researchers studying multi-pathway healing models.

RetaLABS supplies this blend as a 10mg lyophilised vial (approximately 5mg BPC-157 / 5mg TB-500) for researchers who wish to investigate combined administration without requiring separate preparation of each compound.

BPC-157 is a synthetic pentadecapeptide (15 amino acids) derived from a sequence within the gastric juice protein BPC. Its primary research-supported mechanisms include:

• VEGF upregulation — promotes angiogenesis and improved vascularisation in healing tissue
• FAK/paxillin pathway activation — enhances fibroblast migration and extracellular matrix organisation
• Nitric oxide modulation — influences eNOS/nNOS signalling for vasodilation and tissue perfusion
• Growth factor receptor upregulation — including EGFR in tendon and gut tissue models

BPC-157 has a particularly strong evidence base for tendon, ligament, and gastrointestinal repair in rodent models. For full mechanistic detail see the BPC-157 Research Guide.

TB-500 is a synthetic peptide corresponding to the active region of Thymosin Beta-4 (Tβ4) — a ubiquitous 43-amino acid intracellular actin-sequestering protein present in virtually all mammalian cell types. The TB-500 sequence (commonly referencing the Tβ4 active fragment) mediates the following effects in preclinical research:

• Actin regulation — Tβ4/TB-500 sequesters G-actin (monomeric actin), regulating the dynamic equilibrium between G-actin and F-actin (filamentous). This modulates cell motility and morphology, critical processes in wound infiltration and repair
• Anti-inflammatory signalling — TB-500 downregulates inflammatory cytokines and has shown protective effects in cardiac and skeletal muscle injury models
• Endothelial cell migration — TB-500 promotes endothelial cell movement and blood vessel formation, contributing an angiogenic component complementary to BPC-157's VEGF-driven pathway
• Cardiac repair — a distinct body of research examines Tβ4/TB-500 in myocardial infarction models, with documented reductions in cardiomyocyte apoptosis and improved cardiac function indices

BPC-157 and TB-500 address tissue repair through mechanistically distinct but convergent pathways:

• Angiogenesis — BPC-157 (VEGF-mediated) and TB-500 (endothelial migration) both promote vascularisation of healing tissue through different receptor and signalling mechanisms, potentially producing additive effects
• Cell migration — TB-500's actin regulatory activity and BPC-157's FAK/paxillin signalling both promote cellular infiltration of wound sites; one operates at the cytoskeletal level, the other at the adhesion complex level
• Anti-inflammatory coverage — both compounds independently reduce local inflammatory markers in their respective model systems, providing multi-pathway inflammatory modulation
• Tissue specificity — BPC-157's evidence is strongest in tendon/ligament and gastrointestinal models; TB-500's evidence extends to cardiac and skeletal muscle, giving the combination broader tissue coverage than either compound alone

This combination has become one of the most commonly investigated peptide stacks in musculoskeletal and wound healing research precisely because the two mechanisms are additive rather than duplicative.

RetaLABS BPC-157 / TB-500 Blend 10mg is in stock and ships Express Post Australia-wide within 1–2 business days of confirmed payment. COA-backed, manufactured to research-grade purity standards. Crypto payments only — Bitcoin, Litecoin, Monero via BTCPay.

Reconstitution: add bacteriostatic water slowly along the vial wall, gently swirl until dissolved. Do not shake or vortex. Store lyophilised at −20°C; reconstituted solution at 2–8°C for up to 4 weeks. Avoid repeated freeze-thaw cycles.

For researchers requiring individual dose control of each component, RetaLABS also stocks BPC-157 20mg as a separate vial. See the Peptide Reconstitution Guide for full protocol notes. For laboratory research use only.